Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and … Continue reading “QualityStocksNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma”
Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need With secured delivery mechanisms and manufacturing contract in hand, Cybin appears well positioned to capitalize on growing market trend … Continue reading “Cybin Corp. Potentially Poised to be First Company Bringing Psychedelic Medicine to Treat Major Depressive Disorder”
Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest fuels this sector in an era where psychedelics, once a taboo substance, are being viewed in a powerful new light. … Continue reading “QualityStocksNewsBreaks – Cybin Corp. Advancing ‘Fungi-Derived’ Products Amid Mushrooming Interest in Psychedelics”
Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more Interest in serotonergic psychedelics has dramatically increased within last decade Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc. For decades seen as a taboo substance, psychedelics today are being viewed in a … Continue reading “Cybin Corp. Emerging as Leader in Growing Psychedelics Space”
Cybin Corp. is Canada’s premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi. A recent article discussing the company reads, “In particular, Cybin aims to further build upon and expand its intellectual property (‘IP’) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic … Continue reading “QualityStocksNewsBreaks – Why Cybin Corp. Is ‘One to Watch’”
Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products) Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in … Continue reading “Cybin Corp. is “One to Watch””
Cybin Corp., Canada’s premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at … Continue reading “QualityStocksNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film”
Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will … Continue reading “QualityStocksNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement”
Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market. The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product … Continue reading “Cybin Corp.”
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company that is advancing its clinical pipeline through its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine, today announced that its research partner and lead investigator, Dr. Michael Hoffer, has obtained a sustainable supply of psilocybin under a … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Research Partner Secures Steady Psilocybin Supply for Clinical Studies”
